Skip to content

Vaxcyte, Inc. PCVX Free cash flow yield

Free cash flow yield at other companies

Pfizer logo
PfizerPFE
7.8%+4.6pp
Merck & Co. logo
Merck & Co.MRK
4.7%-2.8pp
Moderna logo
ModernaMRNA
-29.4%
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
3.1%+0.6pp
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
-3.8%-1.6pp
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
3.3%+2.2pp

Other financials

Income statement

See full
Operating income-$345.9M-91.3%
Net income-$320.6M-128%
EPS (diluted)-$2.30-121%

Balance sheet

See full
Cash & equivalents$262.3M-24.7%
Total debt$116.3M+33.5%
Total equity$3.0B-6.4%
Total assets$3.3B-0.9%

Cash flow

See full
Operating cash flow-$280.6M-68.8%
CapEx$2.1M-61.2%
Free cash flow-$282.7M-64.7%

Valuation

See full
Market cap$7.43B+72.0%
Enterprise value$7.28B+78.6%

Returns & leverage

See full
Return on equity-30.6%+37.9pp
Debt / equity0.0×
Current ratio7.5×-10.2×

Where this comes from

Calculated from Vaxcyte, Inc.’s reported figures.

Based on trailing twelve months.

The official record: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vaxcyte, Inc.'s free cash flow yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vaxcyte, Inc.'s free cash flow yield?
Vaxcyte, Inc. (PCVX) reported free cash flow yield of -9.3% in Q1 2026.
How has Vaxcyte, Inc.'s free cash flow yield changed year-over-year?
Vaxcyte, Inc.'s free cash flow yield increased by 5.9% year-over-year, from -9.9% to -9.3%.
What is the long-term trend for Vaxcyte, Inc.'s free cash flow yield?
Over 5 years (2020 to 2025), Vaxcyte, Inc.'s free cash flow yield has grown at a 25.8% compound annual growth rate (CAGR), from -3.5% to -11.1%.
What does free cash flow yield mean?
Trailing-twelve-month free cash flow divided by market capitalization at the quarter end. The cash return the business generates relative to its market price.